Anette-Gabriele Ziegler1,2,3, Kerstin Kick1,3, Ezio Bonifacio4,5,6, Florian Haupt1,3, Markus Hippich1,3, Desiree Dunstheimer7, Martin Lang8, Otto Laub9, Katharina Warncke10, Karin Lange11, Robin Assfalg1,3, Manja Jolink1,3, Christiane Winkler1,3, Peter Achenbach1,2,3. 1. Institute of Diabetes Research, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich-Neuherberg, Germany. 2. Forschergruppe Diabetes, Technical University Munich, at Klinikum rechts der Isar, Munich, Germany. 3. German Center for Diabetes Research (DZD), Munich, Germany. 4. DFG Center for Regenerative Therapies Dresden, Technische Universität Dresden, Dresden, Germany. 5. Paul Langerhans Institute Dresden, Helmholtz Center Munich, Faculty of Medicine, University Hospital Carl Gustav Carus, TU Dresden, Germany. 6. Institute for Diabetes and Obesity, Helmholtz Diabetes Center at Helmholtz Zentrum München, Munich-Neuherberg, Germany. 7. Klinikum Augsburg, Klinik für Kinder und Jugendliche, Augsburg, Germany. 8. Berufsverband der Kinder- und Jugendärzte e.V., Landesverband Bayern, Augsburg, Germany. 9. PaedNetz Bayern e.V., Rosenheim, Germany. 10. Department of Pediatrics, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany. 11. Department of Medical Psychology, Hannover Medical School, Hannover, Germany.
Abstract
IMPORTANCE: Public health screening for type 1 diabetes in its presymptomatic stages may reduce disease severity and burden on a population level. OBJECTIVE: To determine the prevalence of presymptomatic type 1 diabetes in children participating in a public health screening program for islet autoantibodies and the risk for progression to clinical diabetes. DESIGN, SETTING, AND PARTICIPANTS: Screening for islet autoantibodies was offered to children aged 1.75 to 5.99 years in Bavaria, Germany, between 2015 and 2019 by primary care pediatricians during well-baby visits. Families of children with multiple islet autoantibodies (presymptomatic type 1 diabetes) were invited to participate in a program of diabetes education, metabolic staging, assessment of psychological stress associated with diagnosis, and prospective follow-up for progression to clinical diabetes until July 31, 2019. EXPOSURES: Measurement of islet autoantibodies. MAIN OUTCOMES AND MEASURES: The primary outcome was presymptomatic type 1 diabetes, defined by 2 or more islet autoantibodies, with categorization into stages 1 (normoglycemia), 2 (dysglycemia), or 3 (clinical) type 1 diabetes. Secondary outcomes were the frequency of diabetic ketoacidosis and parental psychological stress, assessed by the Patient Health Questionnaire-9 (range, 0-27; higher scores indicate worse depression; ≤4 indicates no to minimal depression; >20 indicates severe depression). RESULTS: Of 90 632 children screened (median [interquartile range {IQR}] age, 3.1 [2.1-4.2] years; 48.5% girls), 280 (0.31%; 95% CI, 0.27-0.35) had presymptomatic type 1 diabetes, including 196 (0.22%) with stage 1, 17 (0.02%) with stage 2, 26 (0.03%) with stage 3, and 41 who were not staged. After a median (IQR) follow-up of 2.4 (1.0-3.2) years, another 36 children developed stage 3 type 1 diabetes. The 3-year cumulative risk for stage 3 type 1 diabetes in the 280 children with presymptomatic type 1 diabetes was 24.9% ([95% CI, 18.5%-30.7%]; 54 cases; annualized rate, 9.0%). Two children had diabetic ketoacidosis. Median (IQR) psychological stress scores were significantly increased at the time of metabolic staging in mothers of children with presymptomatic type 1 diabetes (3 [1-7]) compared with mothers of children without islet autoantibodies (2 [1-4]) (P = .002), but declined after 12 months of follow-up (2 [0-4]) (P < .001). CONCLUSIONS AND RELEVANCE: Among children aged 2 to 5 years in Bavaria, Germany, a program of primary care-based screening showed an islet autoantibody prevalence of 0.31%. These findings may inform considerations of population-based screening of children for islet autoantibodies.
IMPORTANCE: Public health screening for type 1 diabetes in its presymptomatic stages may reduce disease severity and burden on a population level. OBJECTIVE: To determine the prevalence of presymptomatic type 1 diabetes in children participating in a public health screening program for islet autoantibodies and the risk for progression to clinical diabetes. DESIGN, SETTING, AND PARTICIPANTS: Screening for islet autoantibodies was offered to children aged 1.75 to 5.99 years in Bavaria, Germany, between 2015 and 2019 by primary care pediatricians during well-baby visits. Families of children with multiple islet autoantibodies (presymptomatic type 1 diabetes) were invited to participate in a program of diabetes education, metabolic staging, assessment of psychological stress associated with diagnosis, and prospective follow-up for progression to clinical diabetes until July 31, 2019. EXPOSURES: Measurement of islet autoantibodies. MAIN OUTCOMES AND MEASURES: The primary outcome was presymptomatic type 1 diabetes, defined by 2 or more islet autoantibodies, with categorization into stages 1 (normoglycemia), 2 (dysglycemia), or 3 (clinical) type 1 diabetes. Secondary outcomes were the frequency of diabetic ketoacidosis and parental psychological stress, assessed by the Patient Health Questionnaire-9 (range, 0-27; higher scores indicate worse depression; ≤4 indicates no to minimal depression; >20 indicates severe depression). RESULTS: Of 90 632 children screened (median [interquartile range {IQR}] age, 3.1 [2.1-4.2] years; 48.5% girls), 280 (0.31%; 95% CI, 0.27-0.35) had presymptomatic type 1 diabetes, including 196 (0.22%) with stage 1, 17 (0.02%) with stage 2, 26 (0.03%) with stage 3, and 41 who were not staged. After a median (IQR) follow-up of 2.4 (1.0-3.2) years, another 36 children developed stage 3 type 1 diabetes. The 3-year cumulative risk for stage 3 type 1 diabetes in the 280 children with presymptomatic type 1 diabetes was 24.9% ([95% CI, 18.5%-30.7%]; 54 cases; annualized rate, 9.0%). Two children had diabetic ketoacidosis. Median (IQR) psychological stress scores were significantly increased at the time of metabolic staging in mothers of children with presymptomatic type 1 diabetes (3 [1-7]) compared with mothers of children without islet autoantibodies (2 [1-4]) (P = .002), but declined after 12 months of follow-up (2 [0-4]) (P < .001). CONCLUSIONS AND RELEVANCE: Among children aged 2 to 5 years in Bavaria, Germany, a program of primary care-based screening showed an islet autoantibody prevalence of 0.31%. These findings may inform considerations of population-based screening of children for islet autoantibodies.
Authors: Kevan C Herold; Brian N Bundy; S Alice Long; Jeffrey A Bluestone; Linda A DiMeglio; Matthew J Dufort; Stephen E Gitelman; Peter A Gottlieb; Jeffrey P Krischer; Peter S Linsley; Jennifer B Marks; Wayne Moore; Antoinette Moran; Henry Rodriguez; William E Russell; Desmond Schatz; Jay S Skyler; Eva Tsalikian; Diane K Wherrett; Anette-Gabriele Ziegler; Carla J Greenbaum Journal: N Engl J Med Date: 2019-06-09 Impact factor: 91.245
Authors: Fergus J Cameron; Shannon E Scratch; Caroline Nadebaum; Elisabeth A Northam; Ildiko Koves; Juliet Jennings; Kristina Finney; Jeffrey J Neil; R Mark Wellard; Mark Mackay; Terrie E Inder Journal: Diabetes Care Date: 2014-06 Impact factor: 19.112
Authors: Jane L Chiang; David M Maahs; Katharine C Garvey; Korey K Hood; Lori M Laffel; Stuart A Weinzimer; Joseph I Wolfsdorf; Desmond Schatz Journal: Diabetes Care Date: 2018-08-09 Impact factor: 19.112
Authors: Stephen R Karpen; Jessica L Dunne; Brigitte I Frohnert; Marjana Marinac; Claudia Richard; Sarah E David; Inish M O'Doherty Journal: Diabetologia Date: 2022-07-22 Impact factor: 10.460
Authors: Kenney Ng; Vibha Anand; Harry Stavropoulos; Riitta Veijola; Jorma Toppari; Marlena Maziarz; Markus Lundgren; Kathy Waugh; Brigitte I Frohnert; Frank Martin; Olivia Lou; William Hagopian; Peter Achenbach Journal: Diabetologia Date: 2022-10-05 Impact factor: 10.460
Authors: Michelle So; Colin O'Rourke; Alyssa Ylescupidez; Henry T Bahnson; Andrea K Steck; John M Wentworth; Brittany S Bruggeman; Sandra Lord; Carla J Greenbaum; Cate Speake Journal: Diabetologia Date: 2022-01-18 Impact factor: 10.122
Authors: David G Ramirez; Mark Ciccaglione; Awaneesh K Upadhyay; Vinh T Pham; Mark A Borden; Richard K P Benninger Journal: Proc Natl Acad Sci U S A Date: 2021-10-12 Impact factor: 11.205
Authors: Ezio Bonifacio; Andreas Weiß; Christiane Winkler; Markus Hippich; Marian J Rewers; Jorma Toppari; Åke Lernmark; Jin-Xiong She; William A Hagopian; Jeffrey P Krischer; Kendra Vehik; Desmond A Schatz; Beena Akolkar; Anette-Gabriele Ziegler Journal: Diabetes Care Date: 2021-02-24 Impact factor: 17.152
Authors: Kimber M Simmons; Jay M Sosenko; Megan Warnock; Susan Geyer; Heba M Ismail; Helena Elding Larsson; Andrea K Steck Journal: J Clin Endocrinol Metab Date: 2020-11-01 Impact factor: 5.958
Authors: Hugo Segerer; Michael Wurm; Julia M Grimsmann; Beate Karges; Andreas Neu; Marina Sindichakis; Katharina Warncke; Axel Dost; Reinhard W Holl Journal: Dtsch Arztebl Int Date: 2021-06-04 Impact factor: 5.594